Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
Name:
e000219.full.pdf
Size:
743.9Kb
Format:
PDF
Description:
Full text open access article
Authors
Blackhall, Fiona HRoss Camidge, D
Shaw, A
Soria, J
Solomon, B
Mok, T
Hirsh, V
Jänne, P
Shi, Y
Yang, P
Pas, T
Hida, T
Carpeño, J
Lanzalone, S
Polli, A
Iyer, S
Reisman, A
Wilner, K
Kim, D
Affiliation
Institute of Cancer Sciences, Manchester University and Christie Hospital NHS Foundation Trust, Manchester, UKIssue Date
2017
Metadata
Show full item recordAbstract
Crizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). We report final results from PROFILE 1005, the largest clinical trial to date for an ALK inhibitor in ALK-positive NSCLC.Citation
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. 2017, 2 (3):e000219 ESMO OpenJournal
ESMO OpenDOI
10.1136/esmoopen-2017-000219PubMed ID
29209525Type
ArticleLanguage
enISSN
2059-7029ae974a485f413a2113503eed53cd6c53
10.1136/esmoopen-2017-000219
Scopus Count
Collections
Related articles
- Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
- Authors: Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A
- Issue date: 2018 Jun
- Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
- Authors: Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR
- Issue date: 2016 Dec
- Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
- Authors: Shi Y, Chen J, Yang R, Wu H, Wang Z, Yang W, Cui J, Zhang Y, Liu C, Cheng Y, Liu Y, Shan J, Wang D, Yang L, Hu C, Zhao J, Cao R, Tan B, Xu K, Si M, Li H, Mao R, Li L, Kang X, Wang L
- Issue date: 2024 Jun
- Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.
- Authors: Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V
- Issue date: 2022 Jan 7
- Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
- Authors: Garcia Campelo MR, Lin HM, Zhu Y, Pérol M, Jahanzeb M, Popat S, Zhang P, Camidge DR
- Issue date: 2021 May